Search
renizgamglogene autogedtemcel
go.drugbank.com/drugs/DB25530Investigationalrenizgamglogene autogedtemcel is a biologic drug. renizgamglogene autogedtemcel is under investigation in clinical trial NCT05444894 (EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in
Synonyms: Autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the HBG1 and HBG2 promoters, autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/Cas12a ribonucleoprotein (RNP) at the HBG1 and HBG2 promotersATR-04
go.drugbank.com/drugs/DB26782InvestigationalATR-04 is a biologic drug. ATR-04 is under investigation in clinical trial NCT04731259 (Study to Evaluate the Safety of ATR-04).
HNF4α srRNA
go.drugbank.com/drugs/DB27228InvestigationalHNF4α srRNA is a biologic drug. … HNF4α srRNA is under investigation in clinical trial NCT06583993 (A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients).
AEF0117
go.drugbank.com/drugs/DB27675InvestigationalAEF0117 is a small molecule drug. AEF0117 is under investigation in clinical trial NCT05554926 (Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects).
NGM707
go.drugbank.com/drugs/DB28351InvestigationalNGM707 is a humanized IgG antibody with specificity for both LILRB1 and LILRB2.
Tovecimig
go.drugbank.com/drugs/DB30220InvestigationalNOV1501 is a biologic drug. … NOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended
ARI-0001
go.drugbank.com/drugs/DB30635InvestigationalARI-0001 is a biologic drug. ARI-0001 is under investigation in clinical trial NCT05641428 (Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL).
Triplizumab
go.drugbank.com/drugs/DB30669Investigationaltriplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized